PURPOSE: Very few tumor molecular markers have been identified that are highly specific for breast cancer cells when applied to blood and bone marrow (BM). Stanniocalcin (STC)-1 is a recently discovered human gene that has been implicated in cellular calcium homeostasis and resistance to hypoxia and is located on chromosome 8p in a region associated with amplification in breast cancer. We investigated STC-1 mRNA as a potential molecular marker for detection of breast cancer metastasis in the blood and BM. EXPERIMENTAL DESIGN: Using the reverse transcriptase-PCR and electrochemiluminescence detection assay to assess for STC-1 mRNA expression, we evaluated 7 breast cancer cell lines, 34 primary breast cancer tumors, and the BM of 71 patients and the blood of 58 patients with American Joint Committee on Cancer stage 0-IV breast cancer. RESULTS: In this cohort of primarily early-stage breast cancer patients, the detection of STC-1 mRNA in the BM and blood significantly correlated with multiple histopathological prognostic factors, including primary tumor size, number of positive lymph nodes, T stage, M stage, N stage, and overall American Joint Committee on Cancer stage. STC-1 mRNA was not detected in the blood or BM of volunteers without cancer. In situ hybridization studies with a STC-1 antisense RNA probe also confirmed STC-1 mRNA expression in breast cancer cell lines and primary breast tumors. CONCLUSIONS: STC-1 is proposed as a novel, specific, and clinically useful molecular marker for detecting occult breast cancer cells in the BM and blood.
PURPOSE: Very few tumor molecular markers have been identified that are highly specific for breast cancer cells when applied to blood and bone marrow (BM). Stanniocalcin (STC)-1 is a recently discovered human gene that has been implicated in cellular calcium homeostasis and resistance to hypoxia and is located on chromosome 8p in a region associated with amplification in breast cancer. We investigated STC-1 mRNA as a potential molecular marker for detection of breast cancer metastasis in the blood and BM. EXPERIMENTAL DESIGN: Using the reverse transcriptase-PCR and electrochemiluminescence detection assay to assess for STC-1 mRNA expression, we evaluated 7 breast cancer cell lines, 34 primary breast cancer tumors, and the BM of 71 patients and the blood of 58 patients with American Joint Committee on Cancer stage 0-IV breast cancer. RESULTS: In this cohort of primarily early-stage breast cancerpatients, the detection of STC-1 mRNA in the BM and blood significantly correlated with multiple histopathological prognostic factors, including primary tumor size, number of positive lymph nodes, T stage, M stage, N stage, and overall American Joint Committee on Cancer stage. STC-1 mRNA was not detected in the blood or BM of volunteers without cancer. In situ hybridization studies with a STC-1 antisense RNA probe also confirmed STC-1 mRNA expression in breast cancer cell lines and primary breast tumors. CONCLUSIONS:STC-1 is proposed as a novel, specific, and clinically useful molecular marker for detecting occult breast cancer cells in the BM and blood.
Authors: Andy C-M Chang; Judy Doherty; Lily I Huschtscha; Richard Redvers; Christina Restall; Roger R Reddel; Robin L Anderson Journal: Clin Exp Metastasis Date: 2014-11-13 Impact factor: 5.150
Authors: Guangzhi Liu; Gong Yang; Bin Chang; Imelda Mercado-Uribe; Miao Huang; Jingfang Zheng; Robert C Bast; Sue-Hwa Lin; Jinsong Liu Journal: J Natl Cancer Inst Date: 2010-05-18 Impact factor: 13.506
Authors: Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-28 Impact factor: 4.254
Authors: Martin Buess; Michal Rajski; Brigitte M L Vogel-Durrer; Richard Herrmann; Christoph Rochlitz Journal: Neoplasia Date: 2009-10 Impact factor: 5.715